Introduction
Potent antiretroviral therapy has transformed HIV/AIDS to a chronic disease by effectively reducing plasma viral load (HIV RNA) [1] , reconstituting the immune system [2, 3] and inhibiting opportunistic infections [4] . Still, many HIV-infected individuals on combination antiretroviral therapy (cART) harbour detectable HIV DNA in peripheral blood mononuclear cells (PBMCs). Elevated PBMC HIV DNA correlates with HIV-associated dementia (HAD) [5] and with milder neuropsychological deficits as well [6] . This PBMC HIV DNA is representative of cellular HIV reservoirs that are established early in infection [7] . Entry of the virus into the brain is believed to occur by way of blood-brain barrier transmigration of monocytes, cells that express CD14 on their surfaces [8] . The burden of HIV DNA within the activated CD14 þ monocyte subset has been implicated in cognitive dysfunction [5, 9] . Peripheral HIV reservoirs correlate to disease progression [10, 11] and are a major target of HIV eradication efforts.
Prior work has linked detectable PBMC HIV DNA (!10 copies/10 6 cells) to cortical and subcortical gray matter atrophy in patients on cART who have undetectable plasma HIV RNA levels [12, 13] . However, the relationship between peripheral HIV DNA and brain structure has not been investigated in treatment-naive individuals with HIV infection; nor have evaluations used HIV DNA isolated from CD14 þ monocytes. In the Southeast Asia Research Collaboration with Hawaii (SEARCH) 001 Cohort Study, failure to eliminate HIV DNA in monocytes was associated with continued neurocognitive impairment more than 3 years after initiating cART [14] . A recent analysis of the cART-naive HIV-positive cohort analysed in the current article (SEARCH 011) found that high HIV DNA levels in CD14 þ monocytes increased the risk of HIV-associated neurocognitive disorders (HANDs) [15] . As shown by a receiver operator characteristic (ROC) curve, CD14 þ HIV DNA ! 45 copies/10 6 cells had a sensitivity of 86% and a specificity of 70% for identifying HAND. Furthermore, proton magnetic resonance spectroscopy (MRS) identified markers of brain neuronal injury and glial dysfunction that were positively linked to CD14 þ HIV DNA [15] . We now examine the relationship of CD14 þ HIV DNA to regional brain volumes.
Materials and methods
Participant selection SEARCH 011 (NCT00782808) was designed as a prospective study to determine the predictive ability of CD14 þ HIV DNA for HAND, to assess brain injury by MRS and to identify abnormal cytokine profiles in cerebrospinal fluid (CSF) among Thai individuals beginning cART for the first time. Community clinicians referred individuals who met Thai Ministry of Public Health criteria for treatment initiation (CD4 þ cell count <350 cells/ml or symptomatic disease) [16] . Due to feasibility issues, individuals were screened for levels of PBMC HIV DNA rather than CD14 þ HIV DNA, as this required less real-time work at screening and because PBMC HIV DNA had correlated strongly to CD14 þ HIV DNA in previous studies [14, 17] . On the basis of the distribution of our preliminary data, and using a doubleblind study design with all clinical staff blinded to HIV DNA levels and laboratory technicians to clinical data, our goal was to enrol 30 cases with more than and 30 cases with fewer than 1000 copies of HIV DNA per 10 6 PBMCs. We further stratified each HIV DNA group by age (greater or less than 35 years) to minimize clustering by age within HIV DNA strata, which could impact cognition.
Individuals were excluded from the study for reasons of head injury, any acute concurrent illness, preexisting neurologic or psychiatric conditions, learning disability, past substance dependence and current use of illicit drugs or a positive urine toxicology test completed at two separate points (screening and entry). We aimed for 60 individuals and enrolled 63 in all. Two individuals were excluded during the entry visit because of opportunistic brain infections (toxoplasmosis and tuberculosis), and a third was dropped from analysis on account of unacceptable MRI data quality caused by noise during acquisition. The result was a sample of 60 cases. All individuals signed consent forms approved by the University of California (San Francisco, California, USA) and the Chulalongkorn Hospital (Bangkok, Thailand) institutional review boards.
Cognitive characterization
Trained nurses performed neuropsychological testing using a battery developed by the WHO for HIV international assessments and modified slightly for feasibility, as previously described [18, 19] . The battery evaluated neuropsychological domains found to be important for HIV. The study neurologist conducted an HIV disease directed neurological examination developed by the AIDS Clinical Trials Group. Physicians and nurses independently interviewed individuals about functional limitations due to cognitive impairment. Proxy informants, when available, also provided information about participants' cognitive and functional status. Cognitive diagnoses were determined by a consensus conference that included the principal investigator (V.G.V.), a US HIV neurologist and a US HIV-trained neuropsychologist guided by the 2007 ('Frascati') diagnostic criteria as explained earlier [15] .
Cell separation and HIV DNA quantification
Detailed methodologies for cell separation and HIV DNA assessment are provided elsewhere [15] . Briefly, monocytes were purified by magnetic bead positive separation according to the manufacturer's guidelines (Miltenyi Biotec, Auburn, California, USA). The purity of the CD14 þ cells was 91.9% (min: 76.9%; max: 98.7%), as determined by multiparameter flow cytometry on every fifth sample for the first 42 cases. CD14 þ separated cells were then frozen in dimethyl sulfoxide (DMSO) and shipped in batches to the University of Hawaii for HIV DNA assays using standard techniques [20] .
Neuroimaging Study participants underwent MRI on a GE Signa HDx 1.5-Tesla scanner (GE Healthcare, software v12-M4, Milwaukee, Wisconsin, USA) with an eight-channel head coil and a standard body coil. For each individual, a high-resolution anatomical volume was acquired with an axial 3D T1-weighted spoiled gradient echo sequence (echo time ¼ 7 ms, repetition time ¼ 11.2 ms, flip angle ¼ 258, 1 mm 3 resolution). Structural (T1-weighted) MRI data were securely transferred and processed by one author (E.B.) using FreeSurfer (version 5.1.0, http:// www.nmr.mgh.harvard.edu/freesurfer) [21] [22] [23] . The procedures include skull-stripping, intensity normalization, Talairach transformation, segmentation of subcortical white matter and deep gray matter structures, and cortical gray/white matter boundary and pial surface reconstruction. Quality assurance of FreeSurfer data processing was done by visual inspection, and cortical surfaces and subcortical segmentations were checked prior to volumetric group analysis. FreeSurfer's estimate of intracranial volume (ICV) is a standard, reliable measure for regional brain volume normalization [24] .
Statistical analysis
We used the ROC-optimized value [15] to dichotomize our study sample into low (CD14 þ HIV DNA <45 copies/10 6 cells) and high (CD14 þ HIV DNA !45 copies/10 6 cells) HIV DNA groups. Group comparisons of demographic and clinical variables were conducted by t-test or chi-squared test. Analysis of covariance (ANCOVA), controlling for age, CD4 þ cell count and ICV, evaluated the associations between HIV DNA group and selected volumes of interest: caudate, putamen, thalamus, globus pallidus, hippocampus, amygdala, nucleus accumbens, brainstem, corpus callosum, cortical and subcortical gray matter, cerebral white matter, cerebellar gray and white matter, total gray matter and lateral ventricles. CD4 þ T-lymphocyte count was log-transformed prior to inclusion in the model. Plasma HIV RNA, a measure of viral control, was dichotomized at 100 000 copies/ml and was tested as a categorical variable both independently and together with CD14 þ HIV DNA group in post-hoc ANCOVA. The analyses utilized StatView 5.0 (SAS Institute Inc., Cary, North Carolina, USA). We defined statistical significance by P value less than 0.05, and trends towards significance by 0.05 P < 0.1.
Results
The individuals [34.7 AE 7.0 years old; 34 (57%) women] were enrolled during March 2009-December 2011. Urine drug screens confirmed that no study participants were using illicit substances or taking psychiatric medications, including methadone, narcotics and antidepressants. By consensus diagnosis, 32 of 60 (53%) were cognitively normal, 14 had asymptomatic neurocognitive impairment (ANI), eight had mild neurocognitive disorder (MND) and six met criteria for HAD. Plasma HIV RNA levels were less than 100 000 copies/ml in 36 individuals (60%). The low (N ¼ 24) and high (N ¼ 36) HIV DNA groups did not differ at baseline in age, education, sex, CD4 þ T-lymphocyte count or plasma or CSF HIV RNA (Table 1) . Plasma HIV RNA level showed a moderate negative correlation with CD4 þ Tlymphocyte count (R 2 ¼ 0.20, P < 0.001) and did not correlate with CD14 þ HIV DNA.
Compared to the group with low plasma viral load, individuals with high HIV RNA levels had larger volumes of lateral ventricles (12 573.0 AE 7117.4 vs. 8375.0 AE 4632.0 ml 3 ; P ¼ 0.016) independently of age and ICV. Volumes of other brain regions did not differ between the high and low plasma viral load groups. Regional volumes for the high and low HIV DNA individual groups are presented in Table 2 . Higher CD14 þ HIV DNA was significantly linked to decreased volumes of nucleus accumbens, brainstem and total gray matter. Subcortical gray matter volume showed a negative CD14 R HIV DNA burden and brain atrophy Kallianpur et al. 1621 The three brain regions with significant volumetric differences by HIV DNA group (brainstem, nucleus accumbens, total gray matter) underwent repeated posthoc ANCOVA within the high and low plasma HIV RNA individual groups, covarying for age, CD4 þ cell count and ICV. High HIV DNA was associated with smaller nucleus accumbens volume (P ¼ 0.006) in individuals with high HIV RNA, and with smaller brainstem volume (P ¼ 0.087) in those with low viral load. The association between HIV DNA and total gray matter volume, which was marginally significant (P ¼ 0.045) within the entire study sample, did not reach significance in the smaller groups with high or low plasma HIV RNA.
Discussion
Baseline data from this study upheld the hypothesis that the reservoir burden of HIV DNA in peripheral monocytes (CD14 þ ) correlates with damage in brain regions known to be affected by HIV. Moreover, our data add credence to growing concern that the deferral of therapy until progression to symptomatic HIV disease may be accompanied by structural brain changes directly associated with intracellular HIV DNA, although the lack of a comparison group with high CD4 þ T-lymphocyte counts makes it difficult to draw firm conclusions.
The nucleus accumbens and brainstem were significantly smaller in individuals with CD14 þ HIV DNA ! 45 copies/10 6 cells than in those with CD14 þ HIV DNA less than 45 copies/10 6 cells. The nucleus accumbens is of relevance, as its volumetric reduction in HIV-positive patients has been correlated with apathy [25] . Animal models have linked dysfunction of the nucleus accumbens to attentional deficits [26] [27] [28] , which are characteristic of HIV-related cognitive impairment. In the current study, our result is subject to the caveat that nucleus accumbens volume is difficult to obtain by automated algorithms, including that of FreeSurfer. When compared with the gold standard of manual segmentation, larger errors have been reported for volumes of nucleus accumbens and globus pallidus due to the disproportionate effect of discrepancies in the boundary segmentation of small brain structures [29] . CD14 þ HIV DNA ! 45 copies/10 6 cells was also associated negatively with total gray matter volume and with a trend towards decreased volume of subcortical gray matter.
Our findings are broadly consistent with our earlier work associating regional brain atrophy with detectable PBMC HIV DNA in cART-treated, virally suppressed HIVpositive study participants in Hawaii. However, some differences are evident. In particular, the previous volumetric study noted smaller subcortical and cerebellar gray matter volumes in individuals with detectable PBMC HIV DNA. Discrepancies between the current and past work are attributable to dissimilar patient characteristics and study methods. The SEARCH 011 and Hawaii cohorts differed in individual ethnicity, viral clade, use of cART and suppression of HIV RNA. In addition, because peripheral monocyte HIV DNA 1622 AIDS 2014, Vol 28 No 11 reservoirs have been increasingly implicated in the persistence of HAND, SEARCH 011 focused on HIV DNA in CD14 þ monocytes, whereas our earlier studies included T-lymphocyte HIV DNA in the total PBMC pool.
We considered the possibility that high viral load, low CD4 þ cell count and so on (factors characteristic of an untreated population such as the SEARCH 011 cohort) may confound the impact of CD14 þ HIV DNA. In an attempt to mitigate such effects, we included analyses that dichotomized HIV RNA levels as high vs. low. This approach had little impact on our findings but does not exclude the possibility that other processes occurring in the absence of cART (e.g. inflammation) alter brain volumes and hence affect the associations we investigated.
Because the reported duration of HIV infection is unreliable in the setting of our study, we did not consider this variable in our models. Higher plasma viral load (but not CD14 þ HIV DNA) was significantly associated with dilatation of the lateral ventricles, a manifestation of central cerebral atrophy. At the same time, associations of elevated CD14 þ HIV DNA with decreased total and subcortical gray matter volumes indicate that HIV DNA, as well, may contribute to central atrophy. As our previous work did identify a significant association between lateral ventricular enlargement and elevated PBMC HIV DNA [13] , we surmise that high plasma HIV RNA may mask relationships between HIV DNA and brain structure that are more apparent in treated HIV-positive patients.
Effects of viral load may contribute to the lack of associations between HIV DNA and volumes of basal ganglia and striatum. Individuals with high CD14 þ HIV DNA would perhaps show significant volumetric decreases in multiple brain regions compared with an HIV-negative control group, but such assessments were not made.
In summary, CD14 þ HIV DNA ! 45 copies/10 6 cells is associated with reduced volumes of selected brain regions in treatment-naive HIV-positive Thai individuals, corroborating previous reports linking HIV DNA to HAND and to MRS-derived markers of brain inflammation. Our findings strengthen converging evidence of the role of monocytes in the trafficking of HIV to the brain. Early treatment may be indicated to prevent the establishment and persistence of viral reservoirs that lead to cumulative brain injury.
